Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has earned a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two equities ...

Chu's Wicked is now the most-streamed movie for the week of March 17-23, 2025 with 882 million minutes viewed in its first ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 1566.44 with a ...

Though estimates vary, some research suggests that up to 30 percent of men experience symptoms of PE at one point in life or ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Learn more about whether Hims & Hers Health, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Alignment Healthcare, Inc. or Hims & Hers Health, Inc. is a better investment based on AAII's A+ ...